Mergers and Acquisitions

Bristol Myers to buy Karuna Therapeutics for $14B

Karuna’s crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.